Patent Application
20230017523
Proteins and biologics are therapeutics for a range of diseases. Prevalent chronic diseases such as diabetes, anemia and clotting disorders are treated by replenishing defective or deficient proteins. Antibodies and cytokines form the basis for cancer immunotherapy. New protein therapeutics have shown great promise in treating Parkinson's and Huntington's disease and have recently entered clinical trials. Despite their efficacy, long-term delivery of these macromolecules remains a challenge, and direct injection into patients still serves as the primary route of administration. There is a need to develop technologies that can deliver therapeutic proteins for the treatment of chronic conditions. While in vivo gene delivery and genome editing has the potential to correct genetic deficiencies, there are several practical limitations to this approach. Delivery of genetic material to cells is inefficient in vivo, viral vectors like adeno-associated virus (AAV) can contain only a limited amount of genetic information and hence are not suitable for producing larger proteins, there is risk of off-targeting effects in cells, and often the fate of the therapy is directed by the immune reaction to the virus or transformed cells. In contrast, cell-based therapies, where exogenous cells, either natural or engineered to secrete desired proteins, are grafted into the body represent attractive options in long-term, continuous protein delivery. Primary cells sourced from human donor organs and transplanted in patients can take over functions of entire failing organs. Advances in stem cell technology have made it possible to generate unlimited quantities of functionally differentiated cells and organoids including pancreatic β-cells and neurons, suggesting pathways for developing long-term cures for diseases such as diabetes and neurological degeneration. Unlike gene delivery which currently only treats monogenic diseases, engineered cells harboring synthetic gene circuits could perform sophisticated functions and deliver precisely controlled doses of therapeutics on-demand, allowing treatment of complex diseases such as diabetes and autoimmune disorders.
Engineered therapeutic cells hold great promise as cost-effective therapies for several chronic disorders. However, these cells can be immunogenic to the host and their broad application has been limited by the use of immunosuppressants in patients. Devices which can immune-isolate cells and allow the cells to function have emerged as a promising strategy to transplant these cells without chronic immunosuppression. For example, immune-isolating devices have been developed that physically separate the cells from the host immune system while facilitating the passive diffusion of oxygen and nutrients from the host to the cells. Devices that incorporate large numbers of cells, sufficient for therapeutic levels of protein secretion, (sometimes called ‘macrodevices’) have attracted attention owing to their retrievability, clinical promise and safety profiles. Unfortunately, despite decades of intense research, the goal of developing an immune isolating device that remains functional in humans over the long term has yet to be realized.
A device for implantation in a subject may include an electrochemical cell, a circuit electrically coupled to the electrochemical cell, a chamber coupled to the electrochemical cell, and a reservoir configured to hold a set of biological entities. The electrochemical cell is configured to produce oxygen gas from water when a voltage is applied across the electrochemical cell. The electrochemical cell includes a cathode, an anode, and a first membrane disposed between the cathode and the anode. The first membrane is configured to permit passage of cations therebetween. The circuit is configured to provide power to the electrochemical cell and to receive power wirelessly from a remote device. The chamber is configured to receive at least a portion of the oxygen gas produced by the electrochemical cell. The reservoir is configured to receive oxygen gas from the chamber for consumption by the set of biological entities. A second membrane forms a portion of the reservoir. The second membrane is permeable to one or more substances generated by the set of biological entities for delivery of the substances to the subject via the second membrane.
The circuit may include a circuit board. The circuit board may include at least two bond pads disposed thereon. The circuit may be electrically coupled to the electrochemical cell via conductive adhesive bonding between at least part of a surface of the cathode and a first bond pad, and at least part of a surface of the anode and a second bond pad. The circuit may also include at least one light-emitting diode disposed on the circuit board and optically coupled to the reservoir. The light-emitting diode may be configured to generate a light beam to enhance or modulate a function of the set of biological entities. The circuit may also include a microcontroller disposed on the circuit board and configured to modulate a pulse intensity, a pulse frequency, a duty cycle, or a combination thereof, of the at least one light-emitting diode. The at least one light-emitting diode may include a plurality of light-emitting diodes optically coupled to the reservoir. The microcontroller may be configured to multiplex the plurality of light-emitting diodes to sequentially address individual light-emitting diodes of the plurality of light-emitting diodes. The circuit may also include a rechargeable battery. The microcontroller and the battery may be collectively configured to store the received power to the battery and to provide the power stored in the battery to the electrochemical cell.
The device may also include an oxygen sensor disposed in the reservoir or chamber and communicably coupled to the microcontroller. The microcontroller may further be configured to modulate operation of the at least one light-emitting diode to maintain, based on an oxygen level detected by the oxygen sensor, the oxygen level in the reservoir or chamber within a predetermined range.
The device may also include a coating disposed on at least the second membrane. The coating may include an anti-fibrotic substance. The coating may include a zwitterionic compound to prevent or mitigate an accumulation of immune cells, formation of scar tissue, or both. The zwitterionic compound may include at least one of sulfobetaine or phosphocholine polymer modified with at least one of tetrahydropyran phenyl triazole (THPT), (4-(4-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl) phenyl triazole, or N-(4-((1,1-dioxidothiomorpholino)methyl)-1H-1,2,3-triazol-1-yl).
The second membrane may be permeable to oxygen and nutrients. The second membrane may include at least one of polydimethylsiloxane or polycarbonate. The second membrane may include a plurality of pores having a surface coverage of at least 5% of a total surface area of the second membrane, each pore of the plurality of pores independently having a pore diameter of from about 20 nm to about 5 μm.
The chamber may include at least one port to provide fluid communication between a fluid within the chamber and a biological fluid of the subject. In another version, the chamber may include liquid water disposed therein and the chamber may be sealed to prevent fluid communication with fluids outside the chamber. The device may not include a battery or an external oxygen supply. The chamber may be configured to maintain an oxygen partial pressure of about 30 kilopascals to about 50 kilopascals during operation. The anode and the cathode may each comprise at least one of platinum, gold, carbon, iridium, or an oxygen-containing compound.
The set of biological entities may include at least one of primary human cells, stem cell derived cells, cell lines, or xenogeneic cells. The primary human cells may include at least one of hepatocytes, islets, mesenchymal stem cells, human dermal fibroblasts, or neurons. The cell lines may include at least one of Human Embryonic Kidney (HEK) cells, ARPE cells, or CHO-K1 cells. The xenogeneic cells may include pancreatic islets.
A method of making a device for implantation in a subject includes forming a cathode and an anode on either side of a first membrane to fabricate an electrochemical cell, coupling the cathode and the anode to a circuit, forming a chamber disposed on the electrochemical cell, forming a reservoir disposed on the chamber, and covering at least the second membrane with a coating including an anti-fibrotic substance. The first membrane is configured to permit passage of cations between the anode and the cathode, such that during use the electrochemical cell produces oxygen gas from water upon application of a voltage between the anode and the cathode. The circuit is configured to provide power to the electrochemical cell and receive power wirelessly from a remote device. The chamber is configured to receive at least a portion of the oxygen gas produced by the electrochemical cell. The reservoir holds a set of biological entities and is configured to receive oxygen gas from the chamber. The reservoir includes a second membrane forming a portion of the reservoir such that the membrane interfaces with the subject. The second membrane is permeable to one or more substances generated by the set of biological entities for delivery of the one or more substances to the subject via the second membrane.
A method of administering a substance to a subject using a device implanted in the subject includes delivering power wirelessly to a circuit of the device, and applying a voltage across the electrochemical cell of the device via the circuit to generate oxygen gas, such that generated oxygen gas diffuses from the electrochemical cell, through the chamber of the device, and into the reservoir of the device for consumption by the set of biological entities disposed therein, resulting in generation of the substance by the biological entities and subsequent diffusion of the substance across the membrane and the coating for delivery to the subject. The device includes the electrochemical cell configured to produce oxygen gas from water vapor when a voltage is applied across the electrochemical cell. The device also includes the circuit electrically coupled to the electrochemical cell and configured to provide power to the electrochemical cell. The circuit is configured to receive power wirelessly from a remote device. The device also includes the chamber coupled to the electrochemical cell. The chamber is configured to receive at least a portion of the oxygen gas produced by the electrochemical cell. The device also includes the reservoir configured to hold a set of biological entities and receive oxygen gas from the chamber. The reservoir includes a membrane forming a portion of the reservoir. The membrane is permeable to one or more substances generated by the set of biological entities for delivery of the one or more substances to the subject via the membrane. The device also includes the coating disposed on at least one outer surface of the device. The coating includes an anti-fibrotic substance.
A method of implanting a device in a subject includes inserting the device into at least one of a subcutaneous space of the subject or an intraperitoneal space of the subject.
All combinations of the foregoing concepts and additional concepts discussed in greater detail below (provided such concepts are not mutually inconsistent) are part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are part of the inventive subject matter disclosed herein. The terminology used herein that also may appear in any disclosure incorporated by reference should be accorded a meaning most consistent with the particular concepts disclosed herein.
The skilled artisan will understand that the drawings primarily are for illustrative purposes and are not intended to limit the scope of the inventive subject matter described herein. The drawings are not necessarily to scale; in some instances, various aspects of the inventive subject matter disclosed herein may be shown exaggerated or enlarged in the drawings to facilitate an understanding of different features. In the drawings, like reference characters generally refer to like features (e.g., functionally and/or structurally similar elements).
Conventionally, therapeutic agents secreted by cells are administered via direct injection. A typical treatment regimen for a patient prescribed long-term administration of one of these therapeutic agents includes repeated painful injections, which can reduce adherence to the regimen.
Instead of using repeated direct injections, cell-based therapies can be used. Cell-based therapies use exogenous cells, either naturally secreting or engineered to secrete desired therapeutic agents, which are grafted or implanted into a host's body to administer the therapeutic agent to the host. This type of therapy can deliver a therapeutic agent to a patient over a long period of time and/or continuously. These cell-based therapies can be cost-effective therapies for several chronic disorders. However, these implanted therapeutic cells can be immunogenic to the host, resulting in the formation of fibrotic tissue around the cells and leading to high rates of hypoxia mediated cell death. Previous attempts using implanted cell-based therapies have relied on the host taking immune-suppressing medication (e.g., immunosuppressants) to reduce the formation of fibrotic tissue in order to increase the viability of the implanted therapeutic cells. However, these immune-suppressing medications increase the chances of infection, can have harmful side effects, and are not appropriate for all patients for a wide variety of reasons.
Two challenges to proper function of immune-isolating devices that physically separate implanted therapeutic cells from the host immune system use in vivo are: 1) foreign-body reactions (FBR) to the implanted device that can lead to fibrosis, causing cell death, and 2) an inadequate supply of oxygen to the therapeutic cells encapsulated in the device results in hypoxia-mediated cell death. The subcutaneous (SQ) locations in the host where a device may be more easily implanted and retrieved surgically have low oxygen levels and devices implanted in these regions are prone to fibrosis.
Fibrosis in particular has limited survival of immune-isolating devices implanted within hosts. Conventionally, these devices may have semi-permeable membranes that rely on passive diffusion of oxygen and nutrients, but the semi-permeable membranes have failed previously due to fibrosis. Fibrosis is a pathological wound healing mechanism in which extracellular matrix components including collagen build up. Extracellular components can block the semi-permeable membrane so that diffusion of oxygen and nutrients to the cells is limited or substantially stopped, resulting in cell death. For example, phase 1 trials with the PEC-Encap (Viacyte Inc.) device were paused due to fibrosis and poor engraftment.
In addition to fibrosis, immune-isolating devices have struggled to keep their therapeutic cells alive in oxygen deficient implantation sites. There have been several approaches to providing oxygen to grafted therapeutic cells implanted in a host to mitigate hypoxia-mediated cell death. One approach to mitigate cell death due to insufficient oxygen is to vascularize the device. Vascularization connects the host's vasculature with vasculature in the grafted cells so that the host's vasculature delivers oxygen to the graft. However, this approach has substantially failed to mitigate hypoxia-mediated cell death over long time scales. Prevascularization of the graft site prior to device implantation is another approach, but its outcome is unpredictable, includes multiple surgeries, and the host's immune system is usually suppressed to reduce the risk of cell death. Direct oxygen delivery to encapsulated therapeutic cells is another approach. Direct delivery has shown promise as a method to provide long-term graft viability, suggesting the importance of maintaining oxygen tension for cell survival. However, devices using direct delivery of oxygen typically have to have oxygen supplies refilled periodically (e.g., daily via a cutaneous port), making this approach clinically undesirable. Fibrosis continues to be a problem with this technique.
A well-oxygenated, subcutaneous implant with limited fibrosis provides long term survival and function of protein-secreting therapeutic cells in vivo. Encapsulating the therapeutic cells within a chamber can increase the length of survival after implantation. The chamber includes a semi-permeable, immune-isolation membrane that acts as a pathway for the diffusion of oxygen and nutrients to the cells from the host and delivery of the therapeutic protein from the cells to the host.
Accordingly, aspects disclosed herein are directed to implantable bioelectronic device(s) (also sometimes referred to macrodevices) that encapsulate biological entities (e.g., primary human cells, stem cell derived cells, cell lines, xenogeneic cells, or other therapeutic cells) to shield them from immunogenic effects in the body in order to increase their long-term survival without the use of immune-suppressing medication. The bioelectronic device generates its own oxygen supply to create an oxygen-rich microenvironment for the cells and prevents immunogenic attack by physically isolating the therapeutic cells from the host's immune system. The bioelectronic device does not need an external oxygen source (e.g., direct oxygen supplied periodically via a cutaneous port) to keep the cells viable. The bioelectronic device includes a semi-permeable immune-isolation membrane that simultaneously provides a conduit for the delivery of therapeutic agents secreted by the therapeutic cells to the host and provides the cells access to nutrients from the host. In some embodiments, the bioelectronic device includes an anti-fibrotic coating on its outer surface and/or on its semi-permeable immune-isolation membrane to suppress fibrotic tissue formation on the bioelectronic device which might otherwise suppress or prevent the delivery of the therapeutic agent from the cells to the host and the cells' access to the host's nutrients.
The bioelectronic device 100 includes an electrochemical cell 113 to generate oxygen that includes a cation-conducting membrane 112, electrodes 114a and 114b on either side of the membrane 112. The electrochemical cell 113 is coupled to/supported by (e.g., mounted onto or into) a board 110, upon which a power source 118 and a light source 116 (e.g., a light emitting diode, LED) are disposed. The membrane 112 may be disposed in a cavity 115 in the substrate 110. The cavity 115 may be a hole formed through the thickness of the substrate 110. The power source 118 provides power to the light source 116 and to electrochemical cell's electrodes 114a and 114b for the generation of oxygen via water electrolysis (also called water splitting). The power source 118 may include a battery and/or capacitor that is powered wirelessly or via wired coupling, as described in more detail below. The light source 116 is an optional component that may provide light stimulus to the therapeutic cells encapsulated in the device 100 to stimulate and/or regulate their production of therapeutic agents. The device 100 also includes a gas diffusion chamber 122 in which oxygen generated by the electrochemical cell 113 is stored, and a cell housing chamber 124 (also sometimes referred to as a cell reservoir) in which the therapeutic cells are encapsulated. The device 100 includes a housing 120 that surrounds and protects the other components. One side of the device adjacent to or forming part of the cell housing chamber 124 may include a semi-permeable immune-isolation membrane 126 for the transport of oxygen and nutrients to the cells from the host and for the transport of therapeutic agents from the cells to the host. The immune-isolation membrane 126 can be configured to exclude immune cells (e.g., small lymphocytes having a size of about 5 μm to about 10 μm).
The cell housing chamber 144 houses the therapeutic cells and receives oxygen generated by the electrochemical cell 133 via the gas diffusion chamber 142. A side of the cell housing chamber 144 includes the semi-permeable immune-isolation membrane 146 that transports oxygen, nutrients, and therapeutic agents. The device 130 is encapsulated in a housing 140.
The following description is explained with respect to the device of
In one embodiment, the housing 120 is a low-modulus (e.g., having a Young's modulus of about 50 kPa to about 5 MPa, including all values and sub-ranges in between) silicone elastomer (e.g., polydimethylsiloxane) that is soft, flexible and biocompatible. The housing 120 may have a flexural rigidity (also known as bending stiffness) between 10−5N-m and 10−ll N-m, including all values and sub-ranges in between. The housing 120 may have a thickness of about 20 μm to about 2 mm, including all values and sub-ranges in between. The silicone elastomer has a high permeability to O2, H2O and H2, allowing for efficient transport of reactants and products to the one or more electrochemical cells. Water permeates through silicone via the process of pervaporation (a combination of permeation and evaporation) that substantially excludes solvated salt ions. Because the silicone substantially excludes salt ions, the water inside the device is not conductive enough to create a risk of electrical shorting. In another embodiment, the housing 120 is a microporous parylene, a microporous polyimide, and/or a microporous polyisobutylene, where the micropores facilitate transport of H2O, O2, and H2 and the material itself is not permeable to these species.
The bioelectronic device 100 includes an electrochemical cell 113 that generates oxygen. In one example, the main electrochemical reaction for generating oxygen is water splitting and the cation-conducting membrane 112 is a proton exchange membrane (PEM). The cation-conducting membrane 112 may have a size that is about 20% to about 100% of the area of the device. For example, the cation-conducting membrane 112 may have a size of about 1 cm by 1 cm to about 10 cm by 10 cm, including all values and sub-ranges in between. The thickness of the cation-conducting membrane is about 1 mm to about 2 mm. The cation-conducting membrane 112 preferentially transports hydrogen ions (protons) in a highly specific manner. As an example, a PEM proton-conducting membrane is comprised of a fluoropolymer and is an ionomer with extremely high proton conductivities (e.g., ˜0.1 S/cm) based on a combination of favorable chemistry (e.g., presence of sulfonic acid groups) and morphology (e.g., presence of pores). The PEM may be a commercially available membrane (e.g., Nafion™) having perfluorinated backbones similar to those of existing clinically approved biomaterials (e.g., polytetrafluoroethylene, PTFE).
The electrochemical cell 113 also includes at least one pair of electrodes 114a and 114b disposed on opposite sides of the cation-conducting membrane 112. The electrodes 114a and 114b are made of biocompatible materials such as, for example, thin carbon (e.g., graphite sheets/graphene), inert metals (e.g., gold, iridium, or platinum), an anode catalyst (e.g., iridium-ruthenium oxide), combinations thereof, and/or the like. The electrodes 114a and 114b may be attached to the cation-conducting membrane 112 via conductive epoxy so that the electrical interfaces between the electrodes 114a and 114b and the membrane 112 provide low-impedance charge injection. Alternatively, the electrodes 114a and 114b may be deposited on the membrane 112 via thin film evaporation or sputtering deposition. Alternatively, the cation-conducting membrane 112 may be soldered to electrodes 114a and 114b at interfaces. Alternatively, the electrodes 114a and 114b and cation-conducting membrane 112 may be held together using mechanical compression from the housing 120.
The electrochemical cell 113 is mounted onto or within a flexible board 110. The board 110 may be a flexible printed circuit board (PCB) upon which electronic components are disposed and electrically coupled. All of the electrical components can be selected to operate at low power (e.g., less than 100 mW). The flexible PCB 110 may be constructed from high-quality rolled metal structured into an inert polymeric substrate (e.g., polyimide). The PCB 110 may have a thickness of about 80 μm to about 150 μm (e.g., 120 μm), including all values and sub-ranges in between, so that the PCB 110 is flexible (e.g., having a flexural rigidity of about 10−4 N-m and 10−8 N-m. Surface-mounted electronic components are mounted onto the board via reflow soldering. The layout of the PCB can be easily modified to support a range of ultraminiaturized, commercially available electronic components (e.g., for wireless power harvesting, rectification, and power management and control) without a significant increase in overall device footprint.
The electrochemical cell 113 splits water via electrolysis into hydrogen and oxygen (2H2O→2H2+O2) when a voltage is applied to the electrodes 114a and 114b. The applied voltage is 1.23 V (the thermodynamic water-splitting voltage) to about 2 V, including all values and sub-ranges in between. The half reactions at the anode 114b and cathode 114a, respectively, are 2H2O→4H++O2+4e− (anode) and 4H++4e−→2H2 (cathode). The water reacting at the anode 114b may be water vapor or liquid water. The electrochemical cell 113 preferentially transports protons (H+ ions) generated at the anode 114b to the cathode 114a through the cation-conducting membrane 112. The electrochemical cell 113 does not require liquid electrolytes with ionic salts. H2 is produced at a low rate of about 10 nmol/second (or roughly 1 mL/hour) and is quickly dispersed away from the device 100 because of its solubility in blood. Additionally, H2 exposure is non-toxic to cells and does not affect device performance.
The current (I) generated by the electrochemical cell 113 when the applied voltage is greater than 1.23 V is linearly proportional to the O2 generation rate. Increasing applied voltage between 1.23 V and 2 V results in increasing current and O2 generation rates. The current generated by the electrochemical cell when a voltage greater than 1.23 V is applied at the electrodes is given by: I=nFM, where I is the total current, n is the number of electrons for a single molecule of oxygen (n=4), F is Faraday's constant (F=96,500 C/mole) and M is the molar generation rate of oxygen. In this way, oxygen production can be directly modulated by current through the electrode stack. The electrochemical cell 113 uses currents of about 1 mA to about 10 mA (e.g., 1 mA, 2 mA, 3 mA, 4 mA, 5 mA, 6 mA, 7 mA, 8 mA, 9 mA, or 10 mA), including all values and sub-ranges in between, correspond to oxygen generation rates (OGR) of about 1 nmol/s to about 30 nmol/s (e.g. 1 nmol/s, 5 nmol/s, 10 nmol/s, 15 nmol/s, 20 nmol/s, 25 nmol/s, or 30 nmol/s), including all values and sub-ranges in between. Using the metabolic consumption rate of oxygen in human cells, which is about 10 amol/cell/s to about 50 amol/cell/s, this oxygen generation rate is sufficient to support about 5 million to about 80 million cells with a 10% operational capacity (e.g., a cycling frequency of about 1.6×10−5 Hz (i.e., cycling once per day) to about 1 Hz (i.e., cycling once per second); and a duty cycle of about 4% to about 50%). As an example, the oxygen generating electrochemical cell 113 can rapidly (e.g., in less than 20 minutes) increase O2 levels from less than 2% to greater than 45% while maintaining low current (e.g., less than 4 mA) operation. In this way, the device 100 provides an adequate supply of oxygen to encapsulated cells to prevent hypoxia mediated cell death.
The cation-conducting membrane 112 may be disposed in a water-permeable silicone housing 120. Water may reach the surface of the cation-conducting membrane 112 through a process of pervaporation wherein water first evaporates and dissolves into the silicone polymer through a first surface and then diffuses through the polymer and evaporates out through a second surface that is directly contacting the cation-conducting membrane 112. Once water reaches the cation-conducting membrane surface, the resulting reaction can be broken down into anodic and cathodic half reactions described above. The electrochemical current is given be I=NFM, where I is the current, N is the number of electrons to create a single molecule of oxygen (N=4), F is Faraday's constant (96,500 A-s), and M is the molar oxygen generation rate. Accordingly, M is given by M=INF and is directly proportional to the electrochemical current.
The water used as fuel for the electrochemical reaction generating oxygen may be pure water, water vapor, and/or water from extracellular fluid. As an example, pure water may be added to the electrochemical cell 113 before it is sealed within the housing 120. In this way, the electrochemical cell 113 has an immediate water source for the water splitting reaction once implanted. As another example, the housing 120 may include one or more ports (e.g., ports 148a and 148b in
The bioelectronic device 100 also includes a gas diffusion chamber 122. The gas diffusion chamber 122 acts as a storage chamber for O2 gas generated by the electrochemical cell. Oxygen generated at the electrochemical cell 113 diffuses through a layer of the housing 120 (e.g., made of PDMS) between the electrochemical cell 113 and the gas diffusion chamber 122, and then diffuses through a second layer of the housing 120 between the gas diffusion chamber 122 and the cell housing chamber 124. The gas diffusion chamber 122 may have a volume of about 0.5 cm3 to about 100 cm3, depending on the number of cells encapsulated in the device 100. For example, the gas diffusion chamber 122 may have a size of about 1 cm by about 1 cm by about 0.5 cm or a size of about 10 cm by about 10 cm by about 1 cm, or any value or sub-ranges in between. As an example, during electrochemical cell 113 operation, the gas diffusion chamber 122 may have a locally rich O2 environment (e.g., about 10% to about 50% O2 or about 30 kilopascals to about 50 kilopascals of oxygen partial pressure). The gas diffusion chamber 122 is disposed adjacent to or directly in contact with the anode 114b of the electrochemical cell 113. The gas diffusion chamber 122 may be bonded to the electrochemical cell 113 using simple condensation reactions between the chamber 122 and the electrochemical cell 113 by UV-functionalizing or oxygen-plasma-functionalizing surfaces of both components, disposing one on the other, and then exposing them to UV light or oxygen-rich plasma. The addition of energy to the surface of the components, in the form of an oxygen-rich plasma or direct exposure to high energy UV light breaks Si—O bonds on the silicone surface and creates hydrophilic —OH groups. The —OH groups can then bond with OH groups on the second functionalized silicone surface, where the OH—OH groups condense to form Si—O—Si (two bonded surfaces) and water (a by-product).
The gas diffusion chamber 122 is constructed of biocompatible flexible polymer that is permeable to oxygen gas. For example, the gas diffusion chamber 122 may be made of silicone elastomer, polyurethane, biocompatible epoxy, or a combination thereof. Preferably, the gas diffusion chamber 122 is made of silicone. The gas diffusion chamber 122 may be enclosed on all sides and oxygen gas may diffuse into and out of the chamber 122 through its walls. The thickness of the walls of the chamber 122 can be varied to change the oxygen transport rate across chamber wall, with thicker walls having lower transport rates. As an example, the thickness of the walls of the chamber 122 may be about 50 μm to about 2 mm, including all values and sub-ranges in between. The sidewalls of the gas diffusion chamber 122 may be much thicker (e.g., at least 500 μm thicker) than the top and bottom layers of housing material between the gas diffusion chamber 122 and the cell housing chamber 124 and the electrochemical cell 113, respectively, so that oxygen gas diffuses at a faster rate between the electrochemical cell 113, the gas diffusion chamber 122, and the cell housing chamber 124 than the rate of diffusion of oxygen gas out of the device through the device's sidewalls. The sidewalls may also have a smaller surface area than the layers between the components to preferentially direct oxygen gas diffusion through the components.
The filling rate of the gas diffusion chamber 122 can depend directly on the electrochemical current, the size of the gas diffusion chamber 122, and the thickness of the chamber's walls. Emptying rates depend on diffusive O2 loss through chamber walls and consumption of O2 by the therapeutic cells. Preferably, during operation of the electrochemical cell 113, the filling rate of the chamber is about 8 to about 9 times faster than its emptying rate, allowing for O2 storage for extended periods (e.g., 6-8 hours) without the need for constant operation of the electrochemical cell 113.
The bioelectronic device 100 also includes a cell housing chamber 124 in which the therapeutic cells are encapsulated. The dimensions of the cell housing chamber 124 may be similar to those of the gas diffusion chamber 122. The cell housing chamber 124 houses therapeutic cells with a packing density of about 0.5 million cells per cm2 to about 10 million cells per cm2. The cell housing chamber is disposed on a side of the gas diffusion chamber 122 opposite the side facing the anode 114b. In an example, the cell housing chamber 124 and the gas diffusion chamber 122 share a wall so that the cell housing chamber 124 is stacked directly on top of the gas diffusion chamber 122. The shared wall may be a biocompatible polymer (e.g., silicone elastomer, polyurethane, biocompatible epoxy, or a combination thereof) with a fixed thickness to mediate diffusive oxygen gas transport at a constant and uniform rate from the gas diffusion chamber to the cell housing chamber. The thickness of this wall may be about 10 μm to about 500 μm (e.g., 10 μm, 25 μm, 50 μm, 75 μm, 100 μm, 150 μm, 200 μm, or 500 μm), including all values and sub-ranges in between. The side walls (as in, the walls other than the wall facing the gas diffusion chamber and the wall opposite the wall facing the gas diffusion chamber) of the cell housing chamber 124 may be constructed of the same or similar biocompatible polymer as the shared wall and may have a larger thickness than the other walls to prevent oxygen diffusion out of the sides of the device. The wall of the cell housing chamber 124 opposite the wall facing the gas diffusion chamber 122 includes a porous immune-isolation membrane 126.
The cell housing chamber 124 can house many different types of therapeutic cells and varying amounts of cells to provide different types of treatments. For example, the cell housing chamber 124 can house about 1 million to about 1 billion cells (e.g., 2 million, 5 million, 10 million, 20 million, 30 million, 50 million, or 1 billion), including all values and sub-ranges in between. The bioelectronic device 100 can keep these cells alive and functioning inside of a host for a period of about 1 month to about 10 years (e.g., 1 month, 2 months, 3 months, 6 months, 12 months, 2 years, 5 years, or 10 years).
The porous immune-isolation membrane 126 separates the cells from the host's immune system while facilitating gas and nutrient transport into and out of the cell housing chamber 124. The membrane 126 is adhered to the cell housing chamber 124 using chemical bonding and/or an adhesive (e.g., PDMS-PDMS bonding or silicone-based adhesives). The membrane 126 is made of a biocompatible material and includes a plurality of pores. The membrane 126 has a thickness of 6 μm to about 30 μm, and preferably about 20 μm, for ease of handling. The membrane 126 has a high transport rate for the transport of oxygen and nutrients while blocking the entry of harmful immune elements from the host. The membrane's transport rate is dependent on the membrane's material and pore structure. The membrane 126 excludes cells from the host, including immune cells (e.g., granulocytes, lymphocytes, and macrophages) and other cells (e.g., red blood cells and platelets), using size filtering through pores in the membrane 126.
In one embodiment, the immune-isolation membrane 126 is made of silicone elastomer (e.g., PDMS) and has an ordered and uniform pore structure to provide a uniform high transport rate across the entire surface of the membrane 126. The ordered and uniform pore structure includes pores distributed in a grid (e.g., a simple cubic, face-centered cubic, body-centered cubic, or hexagonal grid pattern), with regular spacing and sizing between pores. The silicone elastomer PDMS has a high diffusivity to O2 of about 0.5×10−5 cm2/s to about 5×10−5 cm2/s, and preferably at least 3.5×10−5 cm2/s, comparable to that of liquid water (2.3×10−5 cm2/s). With this high diffusivity, oxygen transport can occur through the entire surface of the membrane made of PDMS. Because of the membrane's high diffusivity to O2, O2 flux into and out of the cell housing chamber scales linearly with diffusivity (Fick's Law). The pores in the membrane 126 have a diameter of about 20 nm to about 5 μm (e.g., 20 nm, 50 nm, 100 nm, 200 nm, 500 nm, 800 nm, 1 μm, 2 μm, 3 μm, 4 μm, or 5 μm), including all values and sub-ranges in between, to prevent the ingress of harmful immune elements from the host into the cell housing chamber 124. As an example, the pores in the membrane 126 may have a diameter of about 400 nm to about 1 μm. The size of the pores is selected to exclude cells while not excluding molecules (e.g., therapeutic agents). The pores in the membrane 126 have a cross-sectional area of about 314 nm2 to about 20 μm2 (e.g., 314 nm2, 350 nm2, 400 nm2, 500 nm2, 1 μm2, 2 μm2, 5 μm2, 10 μm2, or 20 μm2), including all values and sub-ranges in between. The total open area in the membrane 126 is about 0.5% to about 20%, including all values and sub-ranges in between.
Conventionally, creating a PDMS immune-isolation membrane with an ordered and uniform pore structure with a pore size of 1 μm or less was challenging. Conventional approaches based on demolding from post structures have been used to form pores in the 10 μm range in PDMS, but these approaches have not successfully formed pores in PDMS in the submicron range. The challenge is related to the higher aspect ratios when creating submicron features, which can result in fragile, error-prone fabrication. For example, a membrane with a thickness of 20 μm and pore diameters of 1 μm has an aspect ratio of 20.
As an example, the immune-isolation membrane 126 may be fabricated using a molding process with silicon microneedles (μ-needles). The μ-needle mold and the resulting pore structure in the membrane 126 includes a wide base and a narrow tip to support robust, repeatable molding and demolding cycles. Moreover, conical pores may increase diffusivity as compared to straight pores by up to about a factor of 20. The size of the base of the conical μ-needle and the widest part of the resulting pore in the membrane 126 is about 1 μm to about 20 μm. The size of the tip of the conical μ-needle and the narrowest part of the resulting pore in the membrane 126 is about 400 nm to about 5 μm, and preferably about 1 μm. The membrane 126 may be fabricated using the μ-needle mold using spin-casting and/or compression molding. As an example, liquid PDMS prepolymer may be spin cast or compression molded onto the μ-needle mold and then cured, resulting in a solid membrane with pore sizes determined by μ-needle tip sizes. The μ-needle mold may be fabricated using photolithographic mask techniques and/or isotropic and/or anisotropic etching. Etch rates and photolithographic mask designs can be altered to change the pore size, spacing and geometry in the membrane. The aspect ratios and geometries of the μ-needles can be varied to achieve desired levels of transport. For example, a steeper μ-needle uses alternating periods of isotropic and anisotropic etching, and closer needle spacing uses a tighter pattern on the photolithographic mask.
In step 3, the photoresist and SiO2 layers are removed, the wafer 200c is coated with a liquid PDMS prepolymer 220a, and then the prepolymer 220a is cured. The prepolymer 220a is a substance which represents an intermediate stage in polymerization and can be usefully manipulated before polymerization is completed. In step 4, the cured PDMS layer is removed from the silicon wafer 200c to result in the immune-isolation membrane 220b. In some embodiments, a thin film of polymethylmethacrylate (PMMA) may be spin-coated onto the silicon μ-needle mold and baked to create a hydrophobic surface suitable for PDMS molding prior to adding the PDMS prepolymer 220a in Step 3. Spin coating a PDMS layer onto the microneedle pattern in Step 3 at a carefully controlled speed (about 3000 rpm) can result in a reproducible film thickness matched to the height of the microneedles (about 20 μm). Applying gentle pressure with a hydrophobic sheet provides reproducible pore formation at the sharp needle tips. The resulting porous PDMS film can be reproducibly manufactured at pore sizes (about 600 nm to about 5 μm) and open areas appropriate for immunological protection and enhanced transport.
In another embodiment, the immune-isolation membrane includes another material instead of PDMS. For example, the membrane may be made of polyurethane and may be formed using a micromolding process similar to the one described above. As another example, the membrane may be track-etched polycarbonate (PCT) or polytetrafluoroethylene (PTFE) with pores having a size of about 200 nm to about 2000 nm (e.g., 800 nm).
The power supply 300 shown in
An external microcontroller 312 couples to the transmitter circuit 310 and provides pulsing power to the bioelectronic device based on transistor-transistor logic (TTL) at any desired frequency and duty cycle. A pulsed power mode can be used to fill the gas diffusion chamber in an energy efficient manner. The filling rate is controlled by the pulse frequency, pulse intensity, and duty cycle used to provide power to the electrochemical cell. The duty cycle can be varied between 0.01% and 50% (e.g., 0.01%, 0.05%, 0.1%, 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, or 50%) and the frequency can be varied between 0.0002 Hz and 0.05 Hz (e.g., 0.0002 Hz, 0.0005 Hz, 0.0008 Hz, 0.001 Hz, 0.005 Hz, 0.01 Hz, 0.05 Hz, 0.1 Hz, or 0.5 Hz). As an example, the bioelectronic device used a duty cycle of 50% and a frequency of 0.00083 Hz (10 minutes on, 10 minutes off). As another example, the bioelectronic device may operate for a total of 1 hour per 24-hour cycle using any of the duty cycles and frequencies described above to fill the gas diffusion chamber.
The receiver circuit 320 in the implantable bioelectronic device includes a tuning circuit 322, a rectification circuit 324, and an oxygen generation circuit 326. The tuning circuit 322 includes an L-C oscillator with the inductance (L) and capacitance © tuned to be impedance-matched to the transmitter circuit 310. The tuning circuit 322 includes a tuning capacitor with a capacitance of about 1 picoFarad (pF) to about 200 pF. The rectification circuit 324 includes a buffering capacity with a capacitance of about 1 microFarad (μF) to about 10 μF. The inductor may have an inductance of about 500 nanHenries (nH) to about 15 microHenries (μH). The inductor may be custom-designed and constructed from a thin, dense, rolled copper laminate on a polyimide film. The width and thickness of the traces of the inductor and the number of turns in the inductor coil define the impedance values. The width of the inductor traces may be about 60 μm to about 80 μm (e.g., 75 μm) and the thickness may be about 15 μm to about 25 μm (e.g., 18 μm). The number of turns in the inductor may be about 6 to about 50 (e.g., 6, 10, 12, 24, 30, 36, 40, or 50) and may be placed on one side of the board or both sides of the board. In an example, the inductor includes 12 coils with 6 on the top of the board and 6 on the bottom of the board. In this way, the inductor is etched directly into the circuit board, and, owing to the thin construction of the board (e.g., a total thickness of Cu and polyimide layers of about 110 μm) the entire assembly is mechanically flexible owing to its low flexural rigidity (e.g., about 5 to about 10 N-m). A tuning capacitor in parallel with the inductor completes the impedance matched LC-circuit in the receiver circuit 320. The rectification circuit 324 includes surface-mounted (SMD) diodes and capacitors to complete rectification, while an SMD low-dropout regulator (LDO) ensures steady voltage output (e.g., at 2V), sufficient to power the oxygen generation circuit 326. The choice of LDO can be tuned to achieve any voltage up to an output voltage of about 5 V. The oxygen generation circuit 326 includes the electrochemical cell 342, a regulator 340, and a light-emitting diode (LED) or organic light-emitting diode (OLED) 328. The LED 328 may be used as a light stimulus to modulate the therapeutic cells in the bioelectronic device. A microcontroller may be embedded on the printed circuit board in the bioelectronic device to control the LED 328 and the electrochemical cell 342.
Light delivery by the LED 328 directly to the therapeutic cells in the cell housing chamber may activate gene circuits for dosed drug delivery. This approach is useful when the therapeutic cells are engineered to be responsive to light. The LED 328 may be a single diode or an array of LEDs on the circuit board. The LED 328 can be pulse-width and duty-cycle modulated to control the functioning of the therapeutic cells. The LED 328 is powered and controlled by the power supply 300 and/or a microcontroller in the bioelectronic device. Light intensity may be varied from about 1 mW/mm2 to about 10 mW/mm2 (e.g., 1 mW/mm2, 2 mW/mm2, 4 mW/mm2, 5 mW/mm2, 8 mW/mm2, or 10 mW/mm2), including all values and sub-ranges in between, the frequency may be varied by about 0.0001 Hz to about 0.01 Hz (e.g., 0.0001 Hz, 0.0005 Hz, 0.001 Hz, 0.005 Hz, or 0.01 Hz), including all values and sub-ranges in between, and the duty cycle can be varied by about 5% to about 50% (e.g., 5%, 10%, 20%, 25%, 30%, or 50%), including all values and sub-ranges in between, to vary protein secretion kinetics by the therapeutic cells. LED intensity is varied by a current-limiting resistor in series with the LED. Intensity can be increased by lowering the value of the current limiting resistor in series with the LED. Frequency and duty cycle are programmed into an onboard or external microcontroller. If the LED 328 is an array of LEDs, the microcontroller can multiplex the array of LEDs to sequentially address individual light-emitting diodes in the array. The array can be sequentially pulsed rapidly to increase the circumferential illumination space. The array may be pulsed at a low duty cycle for thermal management to prevent overheating.
The device may include sensors to provide insight into the functioning of the device. For example, one or more sensors may measure oxygen concentrations. The oxygen sensor(s) may be optical based on oxygen quenching or electrical (e.g., a Clark electrode). One or more sensors may also measure biomarkers to quantify device function. For example, the device may include a glucose sensor if it includes cells used to treat diabetes (e.g., islets or pancreatic beta cells). One or more sensors may also measure secreted proteins.
Once the device is assembled, cells are loaded into the cell housing chamber 524. Cells may be loaded through loading ports located on the device using a syringe needle. The cells may be suspended in cell culture medium or an un-crosslinked hydrogel (including an extracellular matrix). The loading port may then be sealed using an adhesive glue that is fast-curing (e.g., fast-curing silicone glues) or UV-curable. If the cells are suspended in an un-crosslinked hydrogel, the hydrogel matrix may be crosslinked by immersing the device in a Ca+ or Ba+-rich bath to facilitate crosslinking and gelation. Cell loading may take place immediately prior to implantation.
The anti-fibrotic coating may include a zwitterionic polymer. The zwitterionic polymer may be a sulfobetaine polymer or a phosphocholine polymer. The zwitterionic polymer may be modified with a small molecule that helps prevent biofouling. The small molecule may be tetrahydropyran phenyl triazole (THPT), (4-(4-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl) phenyl triazole, or N-(4-((1,1-dioxidothiomorpholino)methyl)-1H-1,2,3-triazol-1-yl).
Therapeutic cells or other biological entities encapsulated in the bioelectronic device may be engineered to secrete precisely controlled doses of therapeutic agents on demand, allowing treatment of these complex diseases. The therapeutic cells may be primary human cells (e.g., hepatocytes, islets, mesenchymal stem cells, human dermal fibroblasts, neurons, or a combination thereof). The therapeutic cells may be cell lines (e.g., Human Embryonic Kidney (HEK) cells, ARPE cells, CHO-K1 cells, or a combination thereof). The therapeutic cells may be xenogeneic cells (e.g., pancreatic islets). The bioelectronic device may include a combination of different types of cells. For example, human embryonic kidney (HEK) cells engineered to secrete insulin can be encapsulated in the bioelectronic device to treat diabetes (Type 1 or Type 2) in a host. Retinal epithelial cells (e.g., ARPE-19) engineered to secrete Factor VIII may be encapsulated in the bioelectronic device for the treatment of hemophilia. Endothelial cells (e.g., HUVEC) engineered to secrete Factor IX may be encapsulated in the bioelectronic device also for the treatment of hemophilia. Human dermal fibroblasts may secrete neurotrophic factors for the treatment of neurological disorders including Alzheimer's, Huntington's, and Parkinson's diseases.
Primary cells may be sourced from human donor organs to provide functions of failing organs. For example, pancreatic islets (e.g., from a human or a pig) may be encapsulated in the bioelectronic device to provide functions of the pancreas (e.g., insulin production) for the treatment of diabetes. Other insulin-producing cell lines (e.g., insulinoma) may be used for the treatment of diabetes. Hepatocytes may be encapsulated to be used as liver organoids. Neurons may be encapsulated to provide functions of nervous tissue, including for the treatment of neurological disorders.
As an example, the bioelectronic device 100, 130, and/or 150 can house 20 million ARPE19 cells and keep them viable for 6 months in vivo. The 20 million cells can deliver up to 1 μg of protein per day to the host for the treatment of hemophilia A (HA). HA is a bleeding disorder affecting approximately 20,000 people in the US and 400,000 people worldwide. HA results from a mutation in factor VIII gene (FVIII) resulting in impaired clotting activity with patients having a high risk of life-threatening bleeding and serious complications, including joint and muscle diseases. No effective long-term treatment of HA exists because of the half-life of exogenous FVIII products is less than 24 hours. FVIII replacement through cell-based therapy is promising since relatively low amounts of circulating FVIII (<5% of physiological levels) can reduce the severity of the disease. The ARPE cell line is engineered to secrete FVIII and delivers FVIII over the long-term to the host using the bioelectronic device. The delivery of 1 μg of protein per day to the host from the bioelectronic device is 10-fold higher than the dosage of FVIII used clinically.
In summary, the bioelectronic device provides a microenvironment in which the therapeutic cells can live for an extended period. As an example, the bioelectronic device 100, 130, and/or 150 can be implanted in the host's body and deliver, continuously or intermittently, therapeutic agents to the host from live therapeutic cells encapsulated in the bioelectronic device 100, 130, and/or 150 for about 1 month to about 10 years (e.g., 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 5 years, or 10 years), including all values and sub-ranges in between.
Several types of cells may be encapsulated in the bioelectronic device 100, 130, and/or 150. For example, therapeutic cells that secrete therapeutic agents may be encapsulated in the bioelectronic device 100, 130, and/or 150, where the therapeutic agents can include therapeutic proteins and other biological products (e.g., antibodies, cytokines, growth factors, enzymes, immunomodulators, or thrombolytics). The therapeutic agent is delivered to a host (also sometimes referred to as a patient herein, e.g., a human or another animal) to treat one or more diseases, as described in more detail below. By increasing viability of the therapeutic cells implanted in the host, the bioelectronic device provides long-term treatment by the delivery of therapeutic agents to the host. Non-therapeutic cells may also be encapsulated in the bioelectronic device. For example, cells that regulate sleep cycles may be encapsulated in the bioelectronic device.
Large numbers of cells sufficient to supply therapeutic levels (e.g., minimum effective dose (MED), the lowest dose or concentration that produces a biological response, to the maximum tolerated dose (MTD), highest possible but still tolerable dose level with respect to a pre-specified clinical limiting toxicity) of a therapeutic agent can be encapsulated in the bioelectronic device. For example, the number of cells encapsulated in the device 100, 130, and/or 150 may be up to about 1 billion cells. The number of cells in the device 100, 130, and/or 150 may be selected based on the amount of therapeutic agent that is desired to be delivered to the host. The number of cells in the device influences the amount of therapeutic agent delivered to the host. For example, for the treatment of diabetes, over 350,000 islets (each islet contains many cells) may be used to treat an adult human. The amount of space required to house this many islets is prohibitive unless the islets are packed very closely together (e.g., 5000 islets cm−2 or greater). It is not possible to keep islets viable while this closely packed using conventional devices. The secretion of therapeutic agents and/or delivery of the therapeutic agents to the host can be regulated by the bioelectronic device using heat stimulation, electrical stimulation, and/or light activation, as described in more detail below. In this way, the bioelectronic device 100, 130, and/or 150 controls the dose of therapeutic agent delivered to the host. Encapsulated cells may be primary cells that do not divide or may be immortalized dividing cells. Encapsulated immortalized cells may divide within the device to increase the number of encapsulated cells over time.
The bioelectronic device 100, 130, and/or 150 increases the long-term viability of therapeutic cells implanted in a host by generating oxygen in-situ for the therapeutic cells. The bioelectronic device 100, 130, and/or 150 provides an adequate supply of oxygen to encapsulated cells to prevent hypoxia mediated cell death. The bioelectronic device 100, 130, and/or 150 includes one or more electrochemical cells 113 and/ 133 that generate oxygen using electrolysis of water. This generation can maintain an oxygen partial pressure (pO2) value of about 10% to about 70% (e.g., 10%, 11%, 12%, 13%, 14%, 16%, 18%, 20%, 30%, 40%, 50%, 60%, or 70%), including all values and sub-ranges in between, in the cell housing chamber 124, 144, and/or 164 holding the therapeutic cells. For example, the bioelectronic device 100, 130, and/or 150 can generate oxygen so that the pO2 in the cell housing chamber 124, 144, and/or 164 is about 10% to about 13%, corresponding to values of dissolved oxygen (DO) in arterial blood.
The bioelectronic device 100, 130, and/or 150 expands the range of tissue types in which the therapeutic cells can be implanted to tissues that are oxygen-poor. Hypoxia mediated cell death can result from implanting therapeutic cells in oxygen-poor tissue or from fibrotic tissue formation around the implanted cells. As an example, the bioelectronic device 100, 130, and/or 150 can be located in an oxygen-poor environment (e.g., oxygen-poor tissue including subcutaneous tissue, an intraperitoneal space, an intracranial space, an intraocular space, or an intramuscular space) and still maintain high cell viability as if the therapeutic cells were in a naturally oxygen-rich environment.
Hypoxia mediated cell death can also result from fibrotic tissue formation around the implanted cells. Even a small fibrotic capsule around the cells can result in a significant diffusion barrier for implanted cells, resulting in local hypoxia and cell death. The bioelectronic device can be configured to counteract some of the negative effects of fibrosis. Fibrosis, induced by the foreign body response, is a cause of therapeutic cell death in vivo. Fibrotic tissue can form around the therapeutic cells to reduce or substantially prevent diffusion of oxygen from the host to the cells. The bioelectronic device 100, 130, and/or 150 prevents or substantially reduces hypoxia mediated cell death in at least the following ways. First, the bioelectronic device 100, 130, and/or 150 encapsulates the therapeutic cells and isolates them from fibrotic tissue formation. Second, the bioelectronic device 100, 130, and/or 150 generates its own oxygen supply for the therapeutic cells so that even if fibrotic tissue forms around the device and prevents the diffusion of oxygen from the host to the therapeutic cells, the cells do not experience hypoxia because the generated oxygen creates an oxygen-rich microenvironment in the chamber encapsulating the cells.
In addition to generating its own oxygen, in some embodiments the bioelectronic device 100, 130, and/or 150 also counteracts the negative effects of fibrosis using an anti-fibrotic coating on the outer surface of the device and/or on the device's semi-permeable immune-isolation membrane 126, 146, and/or 166. For example, the anti-fibrotic coating may include a small molecule tetrahydropyran phenyl triazole (THPT) which substantially reduces surface collagen deposition on the bioelectronic device once implanted. Zwitterionic polymers and/or drug eluting crystals may be used to prevent or substantially reduce fibrosis around the device.
While various inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
Also, various inventive concepts may be embodied as one or more methods, of which an example has been provided. The acts performed as part of the method may be ordered in any suitable way. Accordingly, embodiments may be constructed in which acts are performed in an order different than illustrated, which may include performing some acts simultaneously, even though shown as sequential acts in illustrative embodiments.
All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.
The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of” “only one of” or “exactly one of.” “Consisting essentially of” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
This application claims the priority benefit, under 35 U.S.C. 119(e), of U.S. Application No. 63/218,734, filed Jul. 6, 2021, entitled “BIOELECTRONIC DEVICES TO SUPPORT TRANSPLANTED CELLS IN VIVO FOR ENCAPSULATED CELL THERAPIES,” which is incorporated herein by reference in its entirety for all purposes.
This application was made with Government support under Grant No. K99 EB025254 awarded by the National Institutes of Health (NIH). The Government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 63218734 | Jul 2021 | US |
